Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of QX002N versus placebo in active ankylosing spondylitis
ChiCTR2300075284Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of crusekitug in ankylosing spondylitis (AS) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Proportion of subjects achieving ASAS40 at week 16. Started Sep 2023; status: recruiting.
02
Drugs
crusekitug
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2300075284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075284.